Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...